Assembly Biosciences Company Profile (NASDAQ:ASMB)

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences logoAssembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ASMB
  • CUSIP: 92282210
  • Web: www.assemblybio.com
Capitalization:
  • Market Cap: $440.59 million
  • Outstanding Shares: 17,346,000
Average Prices:
  • 50 Day Moving Avg: $23.63
  • 200 Day Moving Avg: $19.19
  • 52 Week Range: $4.88 - $28.18
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $684,369.00
  • Price / Sales: 643.79
  • Book Value: $3.92 per share
  • Price / Book: 6.48
Profitability:
  • EBIDTA: ($47,840,000.00)
  • Return on Equity: -38.29%
  • Return on Assets: -33.08%
Debt:
  • Current Ratio: 7.92%
  • Quick Ratio: 7.92%
Misc:
  • Average Volume: 57,781 shs.
  • Beta: 0.27
  • Short Ratio: 4.55
 

Frequently Asked Questions for Assembly Biosciences (NASDAQ:ASMB)

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) posted its quarterly earnings results on Monday, November, 17th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.84. View Assembly Biosciences' Earnings History.

Who are some of Assembly Biosciences' key competitors?

Who owns Assembly Biosciences stock?

Assembly Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (17.05%), Jennison Associates LLC (11.67%), Perceptive Advisors LLC (3.85%), Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%) and Goldman Sachs Group Inc. (0.36%). View Institutional Ownership Trends for Assembly Biosciences.

Who sold Assembly Biosciences stock? Who is selling Assembly Biosciences stock?

Assembly Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Perceptive Advisors LLC, National Asset Management Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Assembly Biosciences.

Who bought Assembly Biosciences stock? Who is buying Assembly Biosciences stock?

Assembly Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Vanguard Group Inc., Lyon Street Capital LLC, Laurion Capital Management LP, EAM Investors LLC, Geode Capital Management LLC, Victory Capital Management Inc. and Segantii Capital Management Ltd. View Insider Buying and Selling for Assembly Biosciences.

How do I buy Assembly Biosciences stock?

Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Assembly Biosciences stock cost?

One share of Assembly Biosciences stock can currently be purchased for approximately $25.40.

Analyst Ratings

Consensus Ratings for Assembly Biosciences (NASDAQ:ASMB) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Assembly Biosciences (NASDAQ:ASMB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/19/2016William BlairInitiated CoverageMarket Perform -> OutperformN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Assembly Biosciences (NASDAQ:ASMB)
Earnings by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Earnings History by Quarter for Assembly Biosciences (NASDAQ:ASMB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2014Q3 2014($0.49)($1.33)ViewN/AView Earnings Details
4/2/2014($0.28)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Assembly Biosciences (NASDAQ:ASMB)
2017 EPS Consensus Estimate: ($2.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.03)($0.03)($0.03)
Q2 20171($0.79)($0.79)($0.79)
Q3 20171($0.83)($0.83)($0.83)
Q4 20171($0.87)($0.87)($0.87)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Assembly Biosciences (NASDAQ:ASMB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Assembly Biosciences (NASDAQ:ASMB)
Insider Ownership Percentage: 15.90%
Institutional Ownership Percentage: 64.82%
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/11/2016Derek A. SmallCEOBuy10,000$5.53$55,300.00View SEC Filing  
5/27/2014Russell H EllisonCEOBuy13,000$0.92$11,960.00View SEC Filing  
5/23/2014David Jonathan BarrettCFOBuy6,980$0.86$6,002.80View SEC Filing  
5/23/2014Russell H EllisonCEOBuy20,000$0.91$18,200.00View SEC Filing  
5/21/2014Russell EllisonCEOBuy10,000$0.87$8,700.00View SEC Filing  
5/20/2014David Jonathan BarrettCFOBuy40,000$0.88$35,200.00View SEC Filing  
2/5/2013Russell H EllisonCEOBuy15,000$2.55$38,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Assembly Biosciences (NASDAQ:ASMB)
Latest Headlines for Assembly Biosciences (NASDAQ:ASMB)
Source:
DateHeadline
americanbankingnews.com logo Assembly Biosciences Inc (ASMB) Given $16.00 Consensus Price Target by Analysts
www.americanbankingnews.com - May 24 at 8:36 PM
finance.yahoo.com logoAssembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : May 11, 2017
finance.yahoo.com - May 11 at 9:09 PM
americanbankingnews.com logoBrokers Issue Forecasts for Assembly Biosciences Inc's Q2 2017 Earnings (ASMB)
www.americanbankingnews.com - May 11 at 9:16 AM
finance.yahoo.com logoAssembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : May 9, 2017
finance.yahoo.com - May 9 at 9:08 AM
americanbankingnews.com logoBrokerages Expect Assembly Biosciences Inc (ASMB) to Announce ($0.03) Earnings Per Share
www.americanbankingnews.com - May 9 at 12:40 AM
americanbankingnews.com logoAssembly Biosciences (ASMB) Receives Daily Media Impact Rating of 0.20
www.americanbankingnews.com - April 27 at 9:28 AM
americanbankingnews.com logoAnalysts Anticipate Assembly Biosciences Inc (ASMB) to Post ($0.03) Earnings Per Share
www.americanbankingnews.com - April 22 at 12:47 AM
americanbankingnews.com logoAssembly Biosciences (ASMB) Receives Daily News Impact Rating of 0.44
www.americanbankingnews.com - April 20 at 8:29 AM
americanbankingnews.com logoAssembly Biosciences (ASMB) Earns Daily Coverage Optimism Score of -0.10
www.americanbankingnews.com - April 14 at 1:08 PM
americanbankingnews.com logoAssembly Biosciences Inc (ASMB) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 13 at 12:14 AM
americanbankingnews.com logoZacks: Assembly Biosciences Inc (ASMB) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 5 at 3:22 PM
americanbankingnews.com logoZacks: Assembly Biosciences Inc (ASMB) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - March 20 at 12:22 PM
finance.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Financials
finance.yahoo.com - March 8 at 4:21 PM
finance.yahoo.com logoAssembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan
finance.yahoo.com - February 21 at 9:10 AM
streetinsider.com logoAssembly Biosciences (ASMB) Completes Dose Ranging Portion of Phase 1a/1b Trial of ABI-H0731
www.streetinsider.com - February 17 at 6:29 PM
finance.yahoo.com logoAssembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations
finance.yahoo.com - February 16 at 8:34 AM
finance.yahoo.com logoAssembly Biosciences (ASMB) Looks Good: Stock Up 13.9%
finance.yahoo.com - January 18 at 4:18 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
us.rd.yahoo.com - January 10 at 8:43 PM
us.rd.yahoo.com logo8:11 am Assembly Biosciences enters into research, development, collaboration and license agreement with Allergan (AGN); Allergan to make upfront payment of $50 mln
us.rd.yahoo.com - January 10 at 3:42 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,
biz.yahoo.com - January 10 at 3:42 PM
streetinsider.com logoAllergan (AGN) Enters Licensing Agreement with Assembly Biosciences (ASMB) to Obtain Worldwide Rights to GI Programs
www.streetinsider.com - January 9 at 4:29 PM
investopedia.com logoAGN Stock Is Preparing For Battle (AGN)
www.investopedia.com - January 9 at 4:29 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
biz.yahoo.com - December 9 at 8:43 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 6 at 12:37 PM
finance.yahoo.com logoAssembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
finance.yahoo.com - November 11 at 12:59 PM
streetinsider.com logoAssembly Biosciences (ASMB) Commences ABI-H0731 Phase 1 as HBV Treatment
www.streetinsider.com - November 10 at 2:05 PM
zacks.com logoAssembly Biosciences (ASMB) Worth a Look: Stock Up 7.3%
www.zacks.com - October 17 at 8:26 AM
finance.yahoo.com logoAssembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
finance.yahoo.com - September 21 at 8:31 AM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - September 2 at 8:19 AM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
biz.yahoo.com - June 6 at 4:02 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 11 at 4:04 PM
globenewswire.com logoAssembly Biosciences to Webcast Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 19 at 2:59 PM
finance.yahoo.com logoAssembly Biosciences to Webcast Upcoming Investor Conferences
finance.yahoo.com - February 19 at 7:30 AM

Social

Chart

Assembly Biosciences (ASMB) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff